Thomas Jefferson University May 18, 2022 New research finds that the novel coronavirus can make the mouse brain more susceptible to a toxin that induces nerve-cell loss seen in Parkinson’s. PHILADELPHIA – Brain fog, headaches, insomnia are some of the neurological symptoms doctors have observed in COVID-19 patients. Neurological sequelae after a viral infection is not […]
David Sulzer, Angelo Antonini, Valentina Leta, Anna Nordvig, Richard J. Smeyne, James E. Goldman, Osama Al-Dalahmah, Luigi Zecca, Alessandro Sette, Luigi Bubacco, Olimpia Meucci, Elena Moro, Ashley S. Harms, Yaqian Xu, Stanley Fahn & K. Ray Chaudhuri npj Parkinson’s Disease volume 6, Article number: 18 (2020) Cite this article Abstract This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus […]
What is SARS-CoV-2 and COVID-19? National Institute of Neurological Disorders and Stroke Coronaviruses are common causes of usually mild to moderate upper respiratory tract illnesses like the common cold, with symptoms that may include runny nose, fever, sore throat, cough, or a general feeling of being ill. However, a new coronavirus called Severe Acute Respiratory […]
Aron Emmi, Stefania Rizzo, Luisa Barzon, Michele Sandre, Elisa Carturan, Alessandro Sinigaglia, Silvia Riccetti, Mila Della Barbera, Rafael Boscolo-Berto, Patrizia Cocco, Veronica Macchi, Angelo Antonini, Monica De Gaspari, Cristina Basso, Raffaele De Caro & Andrea Porzionato npj Parkinson’s Disease volume 9, Article number: 25 (2023) Cite this articleAbstract Open Access Published: 13 February 2023 Neurological manifestations are common in COVID-19, the disease caused by SARS-CoV-2. Despite reports of SARS-CoV-2 detection in the brain and cerebrospinal fluid of COVID-19 […]
2/11/2022 Morgan Liotta News GT Researchers say the virus aggravates brain cells similar to neurodegenerative conditions, flagging potential future risk, but also treatments. Researchers say the virus aggravates brain cells similar to neurodegenerative conditions, flagging potential future risk, but also treatments. Often characterised primarily as a respiratory disease, SARS-CoV-2 is also linked to neurological symptoms as evidence continues to […]
Salvatore Iacono1† Giuseppe Schirò1† Chiara Davì1 Sergio Mastrilli2 Michelle Abbott3 Fabrizio Guajana1 Valentina Arnao4 Paolo Aridon1 Paolo Ragonese1 Cesare Gagliardo1 Claudia Colomba3 Nicola Scichilone5 Marco D’Amelio1* SARS-CoV-2 infection leading to Coronavirus disease 19 (COVID-19) rapidly became a worldwide health emergency due to its elevated infecting capacity, morbidity, and mortality. Parkinson’s disease (PD) is the second most common neurodegenerative disorder and, nowadays the relationship between SARS-CoV-2 outbreak and […]
Marcelo Merello, Kailash P Bhatia, Jose A Obeso Published: November 27, 2020 DOI: https://doi.org/10.1016/S1474-4422(20)30442-7 Lancet Neurology VOLUME 20, ISSUE 2, P94-95, FEBRUARY 2021 During the pandemic it has become clear that severe acure respiratory syndrome coronavirus (SARS-CoV-2) causes not just respiratory disease, but can affect multiple organs and tissues. Of note is the involvement of the CNS […]
Front. Aging Neurosci., 05 May 2023 Sec. Parkinson’s Disease and Aging-related Movement DisordersVolume 15 – 2023 | https://doi.org/10.3389/fnagi.2023.1138418 Li Wu1† Jun Shen1† Yuhan Jiang1 Xiaolei Shen1 Ping Wang1 Xin Nie2 Wenyan Kang3,4* Jianren Liu1* Wei Chen1* Background: Clinical manifestations of Parkinson’s disease (PD) after Corona Virus Disease 2019 (COVID-19) infection are poorly investigated. Objective: We aimed to explore the clinical features and outcomes of hospitalized PD […]
Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment. Hannah Devlin Science correspondent 28 Aug 2023 03.00 EDT Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients. Bemdaneprocel therapy is at an early stage, and the year-long trial involved just […]
Salvatore Iacono1† Giuseppe Schirò1† Chiara Davì1 Sergio Mastrilli2 Michelle Abbott3 Fabrizio Guajana1 Valentina Arnao4 Paolo Aridon1 Paolo Ragonese1 Cesare Gagliardo1 Claudia Colomba3 Nicola Scichilone5 Marco D’Amelio1* Front. Neurol., 18 May 2023 Sec. Movement Disorders Volume 14 – 2023 | https://doi.org/10.3389/fneur.2023.1172416 SARS-CoV-2 infection leading to Coronavirus disease 19 (COVID-19) rapidly became a worldwide health emergency due to its elevated infecting capacity, morbidity, and mortality. Parkinson’s disease (PD) is the […]
